Elixira: A Feasibility Framework for AI-Guided Nanomedicine in Cancer Prevention

Invented and founded by Tess Fries in 2025, this white paper presents Elixira, a breakthrough technology in AI-guided nanomedicine, designed for autonomous lifelong cancer prevention across all cancer types.

It integrates nanotechnology, artificial intelligence, and self-powered nanoscale energy harvesting to enable real-time, continuous detection and elimination of emerging cancer cells.

Formally introduced under the title “Elixira: A Feasibility Framework for AI-Guided Nanomedicine in Cancer Prevention,” this publication establishes a permanent and citable public record of the invention’s scope and feasibility. It documents the scientific foundations, independent feasibility confirmation by a leading CRO in 2025, and the ethical and societal relevance of transitioning from reactive cancer treatment to proactive lifelong prevention.

This public disclosure secures priority as prior art while maintaining protection of sensitive intellectual property. This work is authored and published by Tess Fries, inventor and founder of Elixira, and constitutes an official public disclosure establishing ownership and authorship.